학술논문
Efficacy and safety of elexacaftor plus tezacaftor plus ivacaftor versus tezacaftor plus ivacaftor in people with cystic fibrosis homozygous for F508del-CFTR: a 24-week, multicentre, randomised, double-blind, active-controlled, phase 3b trial
Document Type
Article
Author
Aurora, Paul; Verhulst, Stijn; Watson, Danie; Lorenz, Michael; Roehmel, Jobst; Gleiber, Wolfgang; Naehrig, Susanne; Stehling, Florian; Sutharsan, Sivagurunathan; van Koningsbruggen-Rietschel, Silke; Fischer, Rainald; Downey, Damian; Haworth, Charles; Duckers, Jamie; Legg, Julian; Barry, Peter; Thursfield, Rebecca; Doe, Simon James; Hilliard, Tom; MacGregor, Gordon; Nash, Edward F; Withers, Nicholas John; Peckham, Daniel; Barr, Helen Louise; Lee, Timothy; Gray, Robert; Vermeulen, Francois; Van Braeckel, Eva; Vanderhelst, Eef; Robinson, Philip J; Wainwright, Claire E; Smith, Daniel J; Mulrennan, Siobhain A; Clements, Barry S; Wark, Peter; McKone, Edward F; Downey, Damian G; Tullis, Elizabeth; Ahluwalia, Neil; Bruinsma, Bote G; Harris, Christopher; Lam, Anna P; Lou, Yiyue; Moskowitz, Samuel M; Tian, Simon; Yuan, Jason; Waltz, David; Mall, Marcus A
Source
In The Lancet Respiratory Medicine March 2022 10(3):267-277
Subject
Language
ISSN
2213-2600